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TGFβ receptor kinase 
inhibitor in renal 
fibrosis
Transforming growth factor-β (TGFβ), 
the central molecule in renal fi brosis, 
activates the activin receptor-like 
kinase 5 (ALK5) receptor, which has a 
cytoplasmic kinase domain. In a study 
by Kim et al., a new small-molecule 
inhibitor of the ALK5 kinase, IN-1130, 
was tested in whole cells and found to 
prevent downstream signaling by the 
purifi ed kinase on activation of Smad3 
phosphorylation with an IC50 value 
of 5 nM. When tested against a large 
panel of serine/threonine and tyrosine 
kinases, the new drug appeared to be 
specifi c for the ALK5 kinase. Using 
unilateral ureteric obstruction, a 
standard model of renal fi brosis, the 
authors treated rats with this agent for 
1 or 2 weeks. Th ey found that the drug 
reduced the parameters usually seen 
in this model, including interstitial 
fi brosis, tubular atrophy, infl ammatory-
cell infi ltration, and fi broblast-cell 
proliferation. Th e drug also reduced 
TGF-1 mRNA, type I collagen mRNA, 
and phosphorylated Smad2. Th ese 
preclinical studies show that this drug 
has promise in preventing the action of 
TGFβ — perhaps the most important 
pathogenic molecule in kidney disease. 
See page 1234.
Angiogenesis in 
polycystic kidney 
disease
One of the important characteristics 
of autosomal polycystic kidney disease 
is the large size of the kidneys, oft en 
reaching masses that fi ll the whole 
abdomen. Although most of this 
increase in size is due to fl uid-fi lled 
cysts, there is good evidence of cell 
proliferation and an increase in cell 
mass of the whole kidney as well. 
Th is raises the question of whether 
cystogenesis is also associated with 
angiogenesis, in a manner similar to 
tumor growth. As they report in this 
issue, Bello-Reuss and colleagues 
injected resin into the renal vasculature 
and studied the shape and extent of the 
renal vascular system aft er dissolving 
the rest of the kidney with the use of 
scanning electron microscopy. Th ey 
found that cysts were surrounded by a 
well-defi ned vascular network, forming 
a capsule-like structure similar to that 
found in tumors. Th ey also found a 
number of abnormal morphologies 
in the blood vessels, including larger 
capillaries, fl attened, spiral arterioles, 
damaged glomeruli, and atresic venules. 
Capillary sprouting, considered the 
hallmark of angiogenesis, was seen in 
the same areas. Th ese studies highlight 
the presence of angiogenesis around the 
cysts, leading the authors to suggest that 
antiangiogenesis therapies might form 
a new kind of treatment for polycystic 
kidney disease. See page 1261.
Oxalobacter in 
primary hyperoxaluria
Primary hyperoxaluria is a severe 
genetic disease wherein calcium 
oxalate depositions in the kidney 
in the form of nephrocalcinosis or 
kidney stones lead to early renal 
failure. Th ere is no treatment for the 
inexorable deposition of the crystals. 
However, oxalate is both absorbed 
and secreted in the intestine. Hence, 
colonic degradation of endogenous 
oxalate secreted from the blood could 
off er a therapeutic option, at least in 
principle. As they report in this issue, 
Hoppe et al. fed patients Oxalobacter 
formigenes, an organism that generates 
an oxalate-degrading enzyme. Th e 
bacteria were given as a frozen paste 
of live cells or freeze-dried material. 
Nine patients received the treatment 
for 4 weeks. Th ose who had normal 
renal function at the beginning of the 
study reduced their oxalate excretion 
by 22%–48% when fed the live bacteria 
and up to 90% when fed the freeze-
dried material. In patients with already 
established renal failure, the treatment 
reduced plasma oxalate concentrations. 
When the retention of the bacteria 
was measured, there was no signifi cant 
long-term colonization of the 
gastrointestinal tract. For a disease 
with no therapy, these results suggest 
a novel and interesting biological 
treatment that appears to be safe and 
eff ective in these short-term studies. 
See page 1305.
Thiazolidinediones in 
renal disease
Th e discovery of thiazolidinediones 
(TZDs), agents that activate the 
peroxisome proliferator-activated 
receptor γ (PPARγ) to increase 
insulin sensitivity, has been one of the 
major recent triumphs of molecular 
pharmacology. In part, the excitement 
deals with the bewildering variety of 
salutary eff ects that these drugs seem to 
exert on a variety of diseases, in addition 
to their well-known results in the 
treatment of diabetes. A large number 
of clinical and experimental studies 
have shown that these drugs exert 
benefi cial eff ects on the cardiovascular 
system beyond their eff ects on glycemic 
control. Th ese include lowering blood 
pressure, reducing triglycerides, 
elevating high-density lipoprotein–
cholesterol, and reducing subclinical 
vascular infl ammation. Moreover, data 
from several animal and human studies 
suggest that TZDs reduce urine albumin 
excretion and may prevent development 
of renal injury. Sarafi dis and Bakris 
summarize these studies in a Review in 
this issue. See page 1223.
